Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...

Dependency on future regulatory approvals for PYRUKYND and potential launches in thalassemia ... sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Bone marrow transplantation is a costly procedure. Depending on the type of transplant the rate may vary from ₹7 lakh to ₹50 ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

Agios Pharmaceuticals Inc (AGIO) reports a 51% increase in net Pyrukynd revenue and outlines promising future launches and ...

USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 ...

Agios Pharmaceuticals (AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to less than18 years with PK ...

Cardiovascular and Pulmonary Research Laboratory, Department of Medicine, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado 80045, United States Cardiovascular and Pulmonary ...

Dr Ravinder K Gupta, Dr Akhilpreet Kaur Anemia is a serious global public health problem that particularly affects young ...

His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, reaffirmed Bahrain’s commitment ...

By Balambal Suryanarayanan CRISPR-Cas9 is a repurposed gene editing tool that allows scientists to cut, replace, and insert pieces of DNA in precise regions along the strand. Courtesy of NIH Image ...